FDA requires validation of AI algorithms in clinical trials: what changes to sponsors

Sponsors of clinical trials that employ artificial intelligence in study operations have to formally validate these algorithms before the FDA. The new orientation of the American agency shifts the requirement of the software layer — which already needed documented quality controls — to the algorithm layer, charging quality assurance systems equivalent to those applied to data integrity. In practice, it is not enough for the system to function: it is necessary to prove how each model reaches the result that guides a decision within the study.

What does FDA AI validation mean in practice?

Validating an algorithm in the regulatory vocabulary is producing documented evidence that it performs the desired function consistently and traceable. For sponsors, this translates into three fronts: describe what the model does and with which data was built, demonstrate its expected performance and keep records of changes throughout the study.

Guidance also links the algorithm to the study quality system. That is, it ceases to be a technical detail embedded in a platform and becomes an auditable item, with nominated responsible, acceptance criteria and version history. The news was published by Clinical Trial Vanguard.

Why does the FDA require AI validation now?

The logic is simple: in recent decades, validation of computer systems in clinical research has focused on software — login, audit trail, access control, record integrity. AI models, however, do not behave as deterministic software. They produce probabilistic outputs, can be retrained and change response as input data vary.

When an algorithm comes to support patient screening, data monitoring or prioritization of websites, among other operational functions, the risk is no longer only IT and becomes of study quality. The FDA follows this movement closely: it had already indicated an interest in AI for the development of drugs and, in another front, accepted an AI model to predict liver lesions, showing that the theme has advanced from conceptual debate to concrete decisions.

AI validation x model approval: what's the difference?

They're two distinct trails, and confusing them is the most common mistake. The approval of a model as a product — the case of the liver injury algorithm — assesses whether that tool can be used in clinical practice. The new orientation deals with another scope: the algorithms that support the conduct of the test itself. A model does not need to be approved as a device to be used in study operations, but it now needs to be validated as a component of the sponsor quality system.

What does FDA AI validation change for Brazil?

Brazilian sponsors, CROs and research centers participating in studies conducted under American regulation tend to receive this requirement by contract, before any local regulatory movement. In practice, the algorithm validation documentation becomes a deliverable from the technology provider, not an optional attachment.

For developers, this means designing traceability from the beginning: recording model versions, freezing the version used in the study, documented performance metrics and monitoring plan. Those who build AI tools for clinical research need to treat this package as part of the product.

What AI validation guidance still does not solve

The requirement does not create a single certification seal nor defines an acceptable minimum performance level — the criterion remains with the sponsor, who needs to justify it. It also remains open as dealing with drift model in long studies, when the algorithm is retrained midway. And there is, until now, no indication of an inspection schedule publicly disclosed.

Frequently Asked Questions about AI validation in the FDA

Is validation valid for any use of AI in a clinical trial?

Guidance targets algorithms employed in study operations, those that influence driving decisions. The detailed scope and exceptions are in the text of the orientation itself, which should be read case by case.

Who's in charge of validation?

The sponsor of the study. It may outsource the technical execution, but the responsibility for documentation and the quality assurance system remains with those sponsoring the research.

Does this replace existing data integrity requirements?

Nope. The validation of the algorithm adds to the previous controls — it expands the verification layer rather than creating an alternative path to compliance with data integrity rules.